TY  - GEN
AU  - Wray,Sibyl
AU  - Havrdova,Eva
AU  - Snydman,David R
AU  - Arnold,Douglas L
AU  - Cohen,Jeffrey A
AU  - Coles,Alasdair J
AU  - Hartung,Hans-Peter
AU  - Selmaj,Krzysztof W
AU  - Weiner,Howard L
AU  - Daizadeh,Nadia
AU  - Margolin,David H
AU  - Chirieac,Madalina C
AU  - Compston,D Alastair S
TI  - Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
SN  - 1477-0970
PY  - 2020///0708
KW  - Adult
KW  - Alemtuzumab
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - Disease Susceptibility
KW  - Female
KW  - Humans
KW  - Infections
KW  - Interferon beta-1a
KW  - administration & dosage
KW  - Male
KW  - Multiple Sclerosis
KW  - drug therapy
KW  - Recurrence
KW  - Risk Factors
KW  - Time Factors
N1  - Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1177/1352458518796675
ER  -